Dr Mikita was a Director at Pfizer’s Centers for Therapeutic Innovation (CTI) and a member of leadership team at CTI from 2017-2021. He played key roles at CTI that generated 16 clinical candidates, 4 currently in Phase I and 3 in Phase II, and out-licensed 3 other molecules for development to other companies in 11 years span.

Dr. Mikita has profound knowledge and expertise in antibody drug discovery, including bi-specific antibody drugs. He gained extensive experience by acting as a project leader, led cross-functional project teams at CTI, for many antibody drug discovery programs targeting to multiple therapeutic areas including Oncology.

As a Director at Pfizer’s CTI, Dr. Mikita also took responsibility to review and provide critical research/development directions of the full CTI portfolio with over 25 active programs run annually.

Dr. Mikita spent his earlier career as a senior level Scientist at CV Therapeutics (acquired by Gilead), Arete Therapeutics, and Tularik (acquired by Amgen). He received his PhD from Yale University in Molecular Biophysics and Biochemistry.